Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2016
At a glance
- Drugs Maraviroc (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Pharmacodynamics
- Acronyms MIP
- 07 Jun 2017 Biomarkers information updated
- 04 Aug 2016 Planned End Date changed from 1 Jan 2020 to 1 Jan 2022.
- 26 Jan 2016 Changed planned patient number and treatment arms , as reported by ClinicalTrials.gov record.